New stem cell shot for osteoarthritis can reduce pain by 58%

New clinical trial suggests donor stem cell treatment could alleviate knee osteoarthritis symptoms and possibly halting disease progression.

A recent clinical trial conducted by Australian biotechnology firm Magellan Stem Cells has opened new avenues for osteoarthritis treatment, suggesting that stem cell therapy may offer a compelling alternative. The Phase I/II trial assessed the safety and efficacy of MAG200, an off-the-shelf allogeneic (donor) stem cell therapy, on patients suffering from knee osteoarthritis . The results, published in Osteoarthritis and Cartilage Open, indicate that this new treatment could substantially improve joint function, reduce pain and potentially modify the course of the disease.

My take on this: Osteoarthritis (OA) is a progressive joint disorder, recognized as the fourth leading cause of disability worldwide. Affecting over 650 million individuals aged 40 years and above, knee osteoarthritis is associated with increased frailty, and research indicates that frailty may also drive OA development. This chronic condition carries a significant economic and healthcare burden, with total knee replacement (TKR) surgery being the most common treatment when conservative therapies fail. However, TKR has its limitations, with around 20-30% of patients experiencing persistent pain and loss of function post-surgery.

Associate Professor Julien Freitag, the lead researcher of the trial and Magellan Chief Medical Officer, explained that osteoarthritis represents an unmet clinical need as current therapies offer limited pain relief (and may also be associated with significant side effects,) and that the trial results suggest that this therapy could delay or prevent the need for joint replacement surgery.

The trial findings are particularly compelling. Patients receiving MAG200 demonstrated a sustained 58% improvement in pain levels at 12 months, while their quality of life scores more than doubled. Notably, those who received the stem cell treatment showed signs of improved cartilage volume – a marker of disease modification – while the placebo group either remained unchanged or saw their osteoarthritis progress. This trial is one of the first to suggest that a single injection of stem cells could maintain therapeutic benefits beyond four years, marking a significant step forward in OA treatment research.

The implications of these findings are far-reaching. With the growing incidence of OA and increasing rates of joint replacement surgery, the orthopaedic workforce is struggling to meet demand. Studies suggest that the number of orthopedic surgeons will need to increase by 10% every five years to cope with the rising cases of OA. Given these pressures, therapies that could delay or prevent TKR would alleviate both the clinical and economic burden associated with OA.

Explore the latest updates on osteoarthritis treatment and future breakthroughs in this trial HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!